Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

BACKGROUND: Staphylococcus aureus bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15–50%. Treatment typically requires prolonged administration of parenteral therapy, itself associated with high costs and potential catheter-associated c...

Descripción completa

Detalles Bibliográficos
Autores principales: Turner, Nicholas A., Zaharoff, Smitha, King, Heather, Evans, Scott, Hamasaki, Toshimitsu, Lodise, Thomas, Ghazaryan, Varduhi, Beresnev, Tatiana, Riccobene, Todd, Patel, Rinal, Doernberg, Sarah B., Rappo, Urania, Fowler, Vance G., Holland, Thomas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109297/
https://www.ncbi.nlm.nih.gov/pubmed/35578360
http://dx.doi.org/10.1186/s13063-022-06370-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109297/
https://www.ncbi.nlm.nih.gov/pubmed/35578360
http://dx.doi.org/10.1186/s13063-022-06370-1

Ejemplares similares